Home
About Us
Our Company
Our Vision
Our Board of Directors
Our Management Team
Scientific Advisory Board
Products
Telitacicept
Disitamab Vedotin
Product Pipeline
Production and Manufacturing
Quality Assurance
R & D
Renovation Capabilities
Technology Platform
Talent Team
Investors
Information Disclosure
Corporate Governance
IR Contacts
News
Company News
Press Release
Join Us
Recruitment
Working at RemeGen
Contact Us
Company Address
Clinical Trial
Products Consulting
Human Resource
Adverse drug reaction reports
Languages
中文简体
中文繁體
English
Home
About Us
Our Company
Our Vision
Our Board of Directors
Our Management Team
Scientific Advisory Board
Products
Telitacicept
Disitamab Vedotin
Product Pipeline
Production and Manufacturing
Quality Assurance
R & D
Renovation Capabilities
Technology Platform
Talent Team
Investors
Information Disclosure
Corporate Governance
IR Contacts
News
Company News
Press Release
Join Us
Recruitment
Working at RemeGen
Contact Us
Company Address
Clinical Trial
Products Consulting
Human Resource
Adverse drug reaction reports
中文简体
|
中文繁體
|
English
Investors
Listing Documents
Financial Reports
Announcements and Notices
27
2022.04
[Inside Information / Quarterly Results / Overseas Regulatory Announcement - Trading Update] 2022 FIRST QUARTERLY REPORT
25
2022.04
[Annual Report] 2021 ANNUAL REPORT
29
2022.03
[Final Results] ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2021
23
2021.09
[Interim/Half-Year Report] 2021 Interim Report
23
2021.08
[Interim Results] INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2021
28
2021.04
[Annual Report] 2020 ANNUAL REPORT
23
2021.04
[Final Results / Revision of Information in Published Preliminary Results] CLARIFICATION ANNOUNCEMENT RELATING TO THE 2020 RESULTS ANNOUNCEMENT
26
2021.03
[Final Results] ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2020
1
/ 1
Jump To
19
2022.04
Constitutional Documents ARTICLES OF ASSOCIATION
31
2022.03
Constitutional Documents - ARTICLES OF ASSOCIATION
06
2020.11
Constitutional Documents - ARTICLES OF ASSOCIATION
06
2020.11
PROCEDURES FOR SHAREHOLDERS TO NOMINATE AN INDIVIDUAL AS A DIRECTOR OR A SUPERVISOR OF THE COMPANY
06
2020.11
SHAREHOLDERS’ COMMUNICATION POLICY
06
2020.11
BOARD DIVERSITY POLICY
1
/ 1
Jump To
Telephone：0535-3573598
Email：IR@REMEGEN.CN
About Us
Our Company
Our Vision
Our Board of Directors
Our Management Team
Scientific Advisory Board
Products
Telitacicept
Disitamab Vedotin
Product Pipeline
Production and Manufacturing
Quality Assurance
R & D
Renovation Capabilities
Technology Platform
Talent Team
Investors
Information Disclosure
Corporate Governance
IR Contacts
News
Company News
Press Release
Join Us
Recruitment
Working at RemeGen
Contact Us
Company Address
Clinical Trial
Products Consulting
Human Resource
Adverse drug reaction reports
58 Beijing Middle Road, Yantai Shandong, China.
（+86）0535-3573672
ppb@remegen.cn
Company Wechat
Terms of Use
Privacy Policy
Media Resources
© All Right Reserved . ICP：
鲁ICP备11031710号-1
